Loading...
XNAS
AMPH
Market cap1.23bUSD
Dec 05, Last price  
26.77USD
1D
-1.40%
1Q
-9.01%
Jan 2017
45.33%
IPO
167.43%
Name

Amphastar Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:AMPH chart
P/E
7.71
P/S
1.73
EPS
3.47
Div Yield, %
Shrs. gr., 5y
0.85%
Rev. gr., 5y
17.20%
Revenues
713m
+10.62%
118,356,000204,323,000229,681,000210,461,000251,519,000255,165,000240,175,000294,666,000322,357,000349,846,000437,768,000498,987,000644,395,000712,814,000
Net income
160m
+15.98%
7,752,00018,094,00011,862,000-10,699,000-2,787,00010,532,0004,508,000-5,738,00048,939,0001,097,00062,116,00091,386,000137,545,000159,519,000
CFO
213m
+16.28%
19,096,000-1,650,00031,042,00021,052,00010,681,00038,560,00039,209,00038,191,00041,762,00057,266,00097,994,00089,181,000183,503,000213,386,000
Dividend
Jun 11, 20100.3 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
IPO date
Jun 25, 2014
Employees
1,615
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT